News

India’s Pharma Exports Poised to Hit $350 Billion by 2047, Driven by APIs, Biosimilars, and Specialty Generics

Currently the world’s largest supplier of generic medicines, India ranks 11th in pharmaceutical export value. However, by shifting focus toward specialty generics, biosimilars, and innovative drugs, the country aims to secure a place among the top five global pharmaceutical exporters.

• By PharmaNews Live Desk
• New Delhi
• Feb 11, 2025

News

India’s pharmaceutical exports are projected to witness a significant rise, surging from $27 billion in 2023 to $65 billion by 2030, and potentially reaching a staggering $350 billion by 2047, according to a new report by Bain & Company in collaboration with Indian pharmaceutical bodies. 

Currently the world’s largest supplier of generic medicines, India ranks 11th in pharmaceutical export value. However, by shifting focus toward specialty generics, biosimilars, and innovative drugs, the country aims to secure a place among the top five global pharmaceutical exporters. 

Union Minister of Commerce and Industry Piyush Goyal, speaking at the Indian Drug Manufacturers Association’s (IDMA) 63rd Annual Day in Mumbai, emphasized the government’s commitment to this vision. “India has long been the pharmacy of the world. Now we want to change the narrative to ‘India as the healthcare custodian of the world.’ The government is fully committed to achieving this goal by fostering innovation, boosting R&D, and ensuring seamless regulatory processes.” 

APIs to Drive India’s Pharma Boom 

A major growth driver will be India’s shift from a volume-based approach to a value-driven strategy. Active Pharmaceutical Ingredients (APIs), currently valued at $5 billion, are projected to soar to $80-90 billion by 2047. With China controlling 35% of the outsourced API market, India’s API sector stands to benefit from global supply chain diversification efforts, including the U.S. Biosecure Act. The report calls for strengthened domestic API production, bulk drug parks, and self-sufficiency in critical raw materials to solidify India’s role as a global API supplier. 

Biosimilars: A Multi-Billion-Dollar Opportunity 

India’s biosimilar exports, currently valued at $0.8 billion, are expected to grow fivefold to $4.2 billion by 2030 and reach $30-35 billion by 2047. Increased investments in R&D, regulatory simplifications in key markets like the U.S., and expanded production capacity will be crucial to India’s competitiveness in this high-growth segment. “The transition from volume-based to value-led growth is essential for Indian pharma to secure its rightful place in the global market,” said Sriram Shrinivasan, Partner at Bain & Company. “Innovation, including the shift towards specialty generics, biosimilars, and novel products, will be the key to India’s pharmaceutical future.” 

Generic Formulations to Lead Export Expansion 

Currently, generic formulations account for 70% of India’s total pharma exports at $19 billion. By 2047, this figure is expected to reach $180-190 billion. However, to maximize profits and market share, the report suggests that the country must move beyond commodity generics and focus on high-value specialty generics. 

Dr. Viranchi Shah, National President of IDMA, stressed the need for policy support: “India can become one of the leaders in pharma exports, but needs strategic interventions. Bulk drug parks are key to API export growth—India must scale efforts to revive and strengthen its API industry while improving energy supply, waste treatment, and road connectivity.” 

Innovation, Vaccines, and CDMOs: Key Growth Areas 

Beyond APIs, biosimilars, and generics, other areas fueling India’s pharma export growth include vaccines, novel therapies, and contract research & manufacturing. 

• Vaccines: India currently supplies 55-60% of UNICEF’s vaccines, but its value share remains low. Investments in clinical trials and high-value vaccine manufacturing could significantly increase export revenue. 

• Innovative Drugs: The country has over 40 new chemical and biological entities in development, with potential exports reaching $13-15 billion by 2047. 

• CDMOs & CROs: India’s contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) are set to expand, driven by demand from global pharmaceutical companies. 

Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance (IPA), underlined the industry’s economic significance: “The pharmaceutical sector is a major contributor to India’s economy, supporting 2.7 million livelihoods and driving $19 billion in trade surplus. To achieve our 2047 vision, doubling down on pharmaceutical exports is essential.” 

Government, Private Sector Must Align for Growth 

The report highlights that regulatory harmonization, expansion of production-linked incentives (PLI), and increased R&D funding will be key enablers for India’s pharma growth. Private equity and venture capital investments in Indian pharma have surged, with healthcare’s share of PE/VC investments rising from 6% in 2021 to 17% in early 2024. 

Raja Bhanu, Director General of Pharmexcil, summed up India’s ambition: “India’s generics are known for quality, affordability, and scalability. By investing boldly in specialty generics, biosimilars, vaccines, and advanced therapies, we aim to reach the $350 billion export milestone.” 

As India gears up to celebrate its 100th year of independence in 2047, the projections indicate that its pharmaceutical industry is on a trajectory to not only boost economic growth but also establish itself as a global healthcare leader.